1. Introduction {#sec1-molecules-23-01792}
===============

As a traditional Chinese medicine prescription, Simo decoction (SMD) is composed of *Semen arecae*, *Radix linderae*, *Radix aucklandiae*, and *Aurantii fructus*. It has been used abundantly to regulate gastrointestinal function and bloating in clinical applications for a thousand years \[[@B1-molecules-23-01792],[@B2-molecules-23-01792]\]. Literature shows that SMD combined some methods e.g., chewing gum or acupuncture, could enhance bowel function recovery, prevent postoperative ileus, and shorten hospital stay in postoperative patients \[[@B3-molecules-23-01792],[@B4-molecules-23-01792]\]. The positive effects may be due to its participation of the regulation of gastrointestinal hormones of the digestive system, and promotion of gastrointestinal motility by promoting contraction of smooth muscle \[[@B5-molecules-23-01792],[@B6-molecules-23-01792]\]. Despite many clinical treatments having been applied, arecoline, norisobodine, naringin, hesperidin, neohesperidin, and narirutin have been identified as the main effective components \[[@B7-molecules-23-01792],[@B8-molecules-23-01792]\]. Besides, some compounds e.g., narirutin, naringin, hesperidin, neohesperidin, and nobiletin were detected in the plasma of rats \[[@B9-molecules-23-01792]\]. However, chemical compounds of SMD were still not completely identified and systematically classified, and the bioactive ingredients should be further investigated in detail.

The degree to which a drug is protein-bound in plasma has a marked effect on its toxicological, pharmacological, and pharmacokinetic parameters. It is widely believed that only the free concentration, rather than the total drug concentration, can elicit pharmacological responses \[[@B10-molecules-23-01792],[@B11-molecules-23-01792]\]. Human serum albumin (HSA) is the most abundant protein in the circumstance of blood circulation, playing a crucial role of the protein to transport and transmit many endogenous and exogenous constituents such as fatty acids, hormones, and drugs \[[@B12-molecules-23-01792],[@B13-molecules-23-01792]\]. The binding affinity of HSA with drugs is connected to the efficiency of clinical treatment. Therefore, the binding affinity of HSA and drug is an essential parameter that should be carefully analyzed in drug studies \[[@B14-molecules-23-01792]\]. In vitro means have been frequently applied to select HSA ligands from purified extracts of medicinal plants. However, trials based on active compounds need sophisticated and multiple isolation steps which are labor-intensive, time-consuming, and expensive \[[@B15-molecules-23-01792]\]. With the advance of the analytical techniques for active ingredients in complex systems, one method based on ultrafiltration coupled with liquid chromatography mass spectrometry (UF-LC-MS) is considered to investigate the combination between HSA and bioactive compounds \[[@B11-molecules-23-01792],[@B16-molecules-23-01792]\]. Due to its low sample consumption, reuse of receptors (e.g., HSA, enzymes), and obviated need for immobilization, bioactive ingredients have been high-throughput screened and identified via the UF-LC-MS technique \[[@B17-molecules-23-01792]\]. This method enables an efficient separation of the binder--receptor complexes from unbound ingredients \[[@B18-molecules-23-01792]\]. Besides, the binding affinity of the bioactive could be calculated by comparing the ultrafiltration chromatogram and reference chromatogram, by yielding the ratios of the unbound and total amount of single component \[[@B11-molecules-23-01792],[@B19-molecules-23-01792]\]. The structure types could also be obtained by the MS/MS system. In addition, molecular docking has also been employed as a crucial tool to select bioactive components, and has exhibited efficient screening ability from multiple targets with a substantial degree of accuracy, time-saving, and cost-effectiveness in drug discovery \[[@B20-molecules-23-01792],[@B21-molecules-23-01792]\]. It could therefore be an appropriate assistant in the ultrafiltration screening method.

Inspired by the applications mentioned above, a simplified and efficient strategy on the strength of liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-TOF-MS) and ultrafiltration high-performance liquid chromatography molecular docking (UF-HPLC-MD) to investigate the bioactive ingredients in SMD was developed, as depicted in [Figure 1](#molecules-23-01792-f001){ref-type="fig"}. To the best of our knowledge, this is the first time that LC-Q-TOF-MS and UF-HPLC-MD have been integrated in the identification and screening of major bioactive components from SMD. The LC-Q-TOF-MS technique could improve the fast detection of chemical compounds, while UF-HPLC-MD supports an approach for the recognition of bioactive ligands of HSA, predicting their binding sites and illustrating more information about the interaction mechanisms between receptor and active ligands \[[@B22-molecules-23-01792]\]. The present study illustrates and explains the practical application of the bioactive compounds of SMD for the clinical treatment of gastrointestinal diseases.

2. Materials and Methods {#sec2-molecules-23-01792}
========================

2.1. Chemicals and Reagents {#sec2dot1-molecules-23-01792}
---------------------------

SMD, used for gastrointestinal dysmotility in China (approval number: guo-yao-zhun-zi Z20025044; specification: 10 mL/division), was obtained from Hunan Hansen Pharmaceutical Company, Ltd. (Yi Yang, China). HSA was acquired from Sigma Chemical Co. (St. Louis, MO, USA), standards, including arecaidine, arecoline, norisoboldine, linderane, costunolide, dehydrocostus lactone, synephrine, rutin, limonin, eriocitrin, narirutin, naringin, hesperidin, heohesperidin, poncirin, naringenin, hesperetin, nobiletin, tangeretin, and sorbic acid with a purity of over 98%, were purchased from Yuan-ye Bio-Technology Co., Ltd. (Shanghai, China). The formic acid, acetonitrile, and methanol used for HPLC analysis were chromatographic grade and purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China).

2.2. HPLC Conditions {#sec2dot2-molecules-23-01792}
--------------------

An Agilent 1260 HPLC system (Agilent Technologies, Palo Alto, CA, USA), equipped with a quat pump, an automatic sampler with a 20 μL sample loop, a thermostat of column, a diode array detector (DAD), and an Agilent ChemStation (Agilent Technologies, Palo Alto, CA, USA) had been employed to analyze samples. A Waters-XTerra™ C18 column (250 mm × 4.6 mm, 5 μm, Waters Corp., Milford, MA, USA) was performed for the chromatographic separation of SMD.

2.3. Q-TOF-MS Apparatus {#sec2dot3-molecules-23-01792}
-----------------------

Identification of mass spectrum was employed on an accurate mass spectrometer of Agilent 6530 Q-TOF-MS (Agilent Technologies, Palo Alto, CA, USA). Chromatographic separation was employed on an Agilent-ZORBAX SB-C18 column (250 mm × 4.6 mm, 5 μm, Agilent Technologies, Palo Alto, CA, USA), and the effluent of the HPLC mobile phase was split and guided into the electrospray ionization (ESI) source. Parameter conditions were performed as following: capillary voltage, 3500 V; nebulizer pressure, 50 psi; nozzle voltage, 1000 V; flow rate of drying gas, 6 L/min; temperature of sheath gas, 350 °C; flow rate of sheath gas, 11 L/min; skimmer voltage, 65 V; OCT1 RF Vpp, 750 V; fragmentor voltage, 135 V. The spectra data were recorded in the range of *m*/*z* 100--1000 Da in a centroid pattern of full-scan MS analysis mode. The MS/MS data of the selected compounds were obtained by regulating diverse collision energy (18--45 eV).

2.4. Sample Preparations {#sec2dot4-molecules-23-01792}
------------------------

The SMD for ultrafiltration and LC-MS were filtered through a 0.22 μm membrane, then diluted to 1:10 *V*/*V* with a buffer solution of ammonium acetate buffer solution (ABS; 10 mM, pH 7.4) before experiments. The HSA (600 µM) was dissolved in ABS and prepared as the work solution

2.5. UF-HPLC-Based Binding Assay {#sec2dot5-molecules-23-01792}
--------------------------------

The procedure of screening was manipulated according to the approach of previous research and consisted of three steps: incubation, washing, and dissociation \[[@B11-molecules-23-01792],[@B23-molecules-23-01792]\]. Briefly, 100 µL of tested SMD solution was incubated with 200 µL HSA (600 µM) and 200 µL buffer solution for 20 min at 37 °C. Meanwhile, denatured HSA solution (boiled for 15 min in a water bath) was used as the negative control in the same manner. The incubated solutions were then filtered through ultrafiltration devices (Millipore Corp., Billerica, MA, USA) with a 30 kDa molecule weight cut-off membrane (Millipore AmiconUltra-0.5 mL, item: UFC503096) and centrifuged at 14,000× *g* to separate the non-specific ingredients from the HSA-ligand complexes for 15 min at room temperature. The residues were then washed with 200 µL of buffer solution by centrifugation to remove the unbound components three times. The ligands showing specific binding to HSA were then released from the mixtures by elution with 400 µL 50% methanol (pH = 3) for 20 min, and then centrifuged at 14,000× *g* for 15 min at room temperature, a process which was repeated twice. The dissociated filtrates were combined and added to 1000 µL by 50% methanol and then directly analyzed.

2.6. Molecular Docking Study {#sec2dot6-molecules-23-01792}
----------------------------

To further study the coactions of the bioactive ligands with HSA, a molecular docking study which could conjecture the interactions of ligands within the constraint of receptors binding sites was performed in silico. In the prediction, the initial three-dimensional structure of the HSA was acquired from the Protein Data Bank (PDB, ID: 1E7I). The binders and water molecules were removed from the crystal structure of HSA by using PyMOL (Schrödinger LLC, New York, NY, USA) \[[@B11-molecules-23-01792]\]. The 3D structures of the ligands were drawn and converted using ChemBioDraw Ultra and ChemBio 3D Ultra (Cambridgesoft Corp., Waltham, MA, USA) \[[@B11-molecules-23-01792]\].

The AutoDock Vina \[[@B24-molecules-23-01792]\] was employed for the docking simulation of these ligands. The docking steps were performed according to the protocol described by Ma et al. \[[@B25-molecules-23-01792]\], with some modifications. Due to the various molecule sizes, in the first round of docking, each grid computation was calculated covering all amino acid residues of HSA to recognize the binding sites, and the simulation was then performed with flexible docking of all molecules in HSA. The grid was then concentrated on the center of Sudlow's site I (60 Å × 60 Å × 60 Å, 0.375 Å, central coordinates *x* = 30.938, *y* = 13.241, and *z* = 7.960) and Sudlow's site II (60 Å × 60 Å × 60 Å, 0.375 Å, central coordinates *x* = 9.491, *y* = 5.575, and *z* = 18.576), respectively, to find the appropriate binding sites \[[@B11-molecules-23-01792]\]. The calculation of docking score was repeated three times for each ligand. Finally, PyMOL was used to present the docking results.

3. Results and Discussion {#sec3-molecules-23-01792}
=========================

3.1. Optimization of HPLC Conditions {#sec3dot1-molecules-23-01792}
------------------------------------

Because of the complicated compositions of four main traditional Chinese medicines, the adequate separation of the aimed constituents is a challenging and essential procedure for HPLC analysis \[[@B23-molecules-23-01792]\]. The SMD was rich in flavonoids, alkaloids, and lactone compounds, and therefore, in the HPLC analytical procedures, the separation conditions containing the mobile phase system, column detection wavelength (nearly higher absorption), temperature, and so on should be investigated. Acid is known to improve separation for constituents with hydroxyl groups by reducing the tailing of the chromatographic peaks. Therefore, formic acid was added to the mobile phase composed of solvents A (0.1% formic acid in water) and B (acetonitrile) \[[@B26-molecules-23-01792]\], and a flow rate of gradient elution was elected at 0.7 mL/min. In consideration of the variety of constituents in SMD in previous pre-experiments, the solvent gradient of the mobile phase was finally optimized as follows: 15% B for 0--5 min, 15--20% B for 5--15 min, 20--25% B for 15--30 min, 25--65% B for 30--42 min, 65--90% B for 42--45 min. The programmed wavelength was selected at 284 nm via comparison of the higher absorption of the main compounds. The column temperature was maintained at 30 °C and the volume of injection was 5 µL.

3.2. Identification of Constituents in SMD {#sec3dot2-molecules-23-01792}
------------------------------------------

As many as 94 compounds were identified as the main constituents by ESI-Q-TOF-MS in the positive and negative ion mode ([Figure 2](#molecules-23-01792-f002){ref-type="fig"}), and their origin was classified according to the chemical information of single herb and literatures ([Table 1](#molecules-23-01792-t001){ref-type="table"}). Compounds **4**, **5**, **13**, **15**, **33**, **36**, **38**, **41**, **46**, **47**, **53**, **55**, **57**, **59**, **67**, **71**, **73**, **82**, and **86** were unambiguously identified as arecaidine \[[@B27-molecules-23-01792],[@B28-molecules-23-01792]\], arecoline \[[@B27-molecules-23-01792],[@B28-molecules-23-01792]\], norisoboldine \[[@B29-molecules-23-01792]\], linderane \[[@B30-molecules-23-01792],[@B31-molecules-23-01792],[@B32-molecules-23-01792]\], costunolide \[[@B33-molecules-23-01792],[@B34-molecules-23-01792]\], dehydrocostus lactone \[[@B33-molecules-23-01792],[@B34-molecules-23-01792]\], synephrine \[[@B35-molecules-23-01792]\], rutin \[[@B36-molecules-23-01792]\], limonin \[[@B37-molecules-23-01792],[@B38-molecules-23-01792],[@B39-molecules-23-01792]\], eriocitrin \[[@B36-molecules-23-01792],[@B40-molecules-23-01792]\], narirutin \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\], naringin \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\], hesperidin \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\], neohesperidin \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\], poncirin \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\], naringenin \[[@B36-molecules-23-01792]\], hesperetin \[[@B36-molecules-23-01792]\], nobiletin \[[@B36-molecules-23-01792],[@B42-molecules-23-01792]\], and tangeretin \[[@B36-molecules-23-01792],[@B42-molecules-23-01792]\], respectively, by comparison of the retention time, absorption wavelengths, and *m*/*z* values with the standards and values reported in the literature. The remaining compounds could be tentatively assigned by comparing the fragmentation patterns, the accurate mass data (absolute value of error \< 5 ppm), and the formula predictor software ([Table 1](#molecules-23-01792-t001){ref-type="table"}). The chemical structures of these compounds were drawn clearly as shown in [Figure 3](#molecules-23-01792-f003){ref-type="fig"}.

For example, compound **12** had \[M + H\]^+^ ions *m*/*z* at 314.1372 yielding the product ions *m*/*z* at 297.1125 \[M + H-17\]^+^, 265.0839 \[M + H-17-32\]^+^, and 237.0743 \[M + H-17-32-28\]^+^, and compound **14** generated \[M + H\]^+^ ions *m*/*z* at 328.1534 yielding the similar product ions *m*/*z* at 297.1110 \[M + H-31\]^+^, 265.0859 \[M + H-31-32\]^+^, and 237.0627 \[M + H-31-32-28\]^+^, both of which had coincident ions with compound **13** and were tentatively assigned as norboldine \[[@B29-molecules-23-01792],[@B31-molecules-23-01792]\] and isoboldine \[[@B29-molecules-23-01792],[@B31-molecules-23-01792]\], respectively. Similarly, compound **16** was initiatively detected as reticuline according to the ions at 330.1691 \[M + H\]^+^, 299.1472 \[M + H-31\]^+^, and 192.0682 \[M + H-138\]^+^ \[[@B29-molecules-23-01792],[@B31-molecules-23-01792]\].

The sugar parts in *O*-glycosylflavone, such as neohesperidose (1→2) and rutinose (1→6) could be distinguished because neohesperidose in glycosides could yield a stronger abundance of parent nuclei contrasted with rutinose-contained glycosides, and thus could be identified by their characteristic fragmentation behaviors \[[@B36-molecules-23-01792]\]. For example, ion *m*/*z* at 273 of naringin was higher than naritutin, and ion *m*/*z* at 303 of neohesperidin was higher than hesperidin in ESI^+^ mode. Compounds **47** and **50** had the same \[M + H\]^+^ ions at *m*/*z* 597 and molecular formula of C~27~H~32~O~15~. Compound **50** presented product ions *m*/*z* at 451 \[M + H-146\]^+^ and 289 \[M + H-146-162\]^+^, exhibited the same ions with compound **47**, and could yield a much higher abundance of fragment ions at *m*/*z* 289 when compared with that of compound **47** (eriocitrin), suggesting that it contained neohesperidose (1→2), and it was accurately identified as neoeriocitrin. Compound **60** showed \[M + H\]^+^ ion at *m*/*z* 465.1387 and \[M − H\]^−^ ion at *m*/*z* 463.1252, and produced the parent ion at *m*/*z* 303.0861 \[M + H\]^+^, with this compound being preliminarily identified as hesperitin-7-*O*-glucoside. Compound **44** of *m*/*z* 741.2245 \[M − H\]^−^ produced product ions at 579.1833 \[M − H-162\]^--^, 417.1323 \[M − H-2 × 162\]^--^, and 271.0756 \[M − H-3 × 162\]^--^ that was identified as naringenin-7-*O*-triglycoside \[[@B36-molecules-23-01792],[@B40-molecules-23-01792]\]. The remaining ingredients were similarly analyzed and classified by referring to the original medical plants of SMD as shown in [Table 1](#molecules-23-01792-t001){ref-type="table"}.

3.3. Optimization of Screening Conditions {#sec3dot3-molecules-23-01792}
-----------------------------------------

Working factors of pH and temperature influenced the activity of HSA, time of incubation influenced the binding degree of binders, eluting steps removed the disturbance of unbound compounds, and dissolution reagent was necessary for the dissociation of HSA-drug complexes. Optimum conditions in the study were established by referring to related studies \[[@B56-molecules-23-01792],[@B57-molecules-23-01792],[@B58-molecules-23-01792]\] which performed single factor experiments in previous work. This study was performed at 37 °C (physiological temperature) with pH 7.4 (the plasma condition) to provide optimal reaction conditions. HSA concentration (from 100 μM to 800 μM), incubation time (from 0 min to 50 min), eluting time, and dissolution reagent (methanol of diverse concentration and pH) were improved before experiments. The results showed that each bioactive ligand could be obtained with the best binding affinity when the concentration of HSA was 600 μM to avoid competitive binding, and the incubation time was set at 20 min. ABS was employed as an eluting solution in triplicate, and a 50% methanol solution (pH 3) was optimally chosen to dissociate HSA-drug complexes.

3.4. Screening Bioactive HSA Ligands from SMD {#sec3dot4-molecules-23-01792}
---------------------------------------------

Using the above screening method, 15 binders were identified as "tight-binding" ligands ([Figure 4](#molecules-23-01792-f004){ref-type="fig"}). However, not all the binders bound to the HSA are specific ligands because some are just ''frequent hitters'', unselectively clogging the protein by hydrophobic interaction without any specific interactions \[[@B59-molecules-23-01792]\], even though the washing procedures were performed. To distinguish between specific ligands and ''frequent hitters'', the method of ultrafiltration and dissociation could be efficiently combined. In short, if one compound in the complicated sample is able to interact with a specific target receptor, the peak area of the bound constituent will significantly increase in the total ion chromatogram after dissociation from the drug-protein complexes. In this way, the UF-HPLC assay could rapidly screen and identify the ligand-receptor complexes from unbound or nonspecific binding compounds, by directly comparing the chromatogram peak areas between natured and denatured HSA after ultrafiltration, as shown in (a) and (b) in [Figure 4](#molecules-23-01792-f004){ref-type="fig"}.

Based on the variation of the chromatographic proportion before and after incubation with natured and denatured HSA, the real reduced peak areas can be used to determine the degree of affinity between the ligand and the enzyme. The binding degree (*BD*) was calculated as follows:$$BD = \frac{An - Ad}{As} \times 100\%$$ where *As*, *An*, and *Ad* represent the peak areas obtained from the SMD sample, natured and denatured HSA after dissociation, respectively. The results in [Table 2](#molecules-23-01792-t002){ref-type="table"} suggest that flavonoids and alkaloids could exert good affinity activity to HSA. Finally, 13 bioactive ingredients (A--M), containing norisoboldine, eriocitrin, neoeriocitrin, narirutin, hesperidin, naringin, neohesperidin, hesperitin-7-*O*-gulcoside, linderane, poncirin, costunolide, nobiletin, and tangeretin, were preliminarily identified as the specific HSA ligands.

3.5. Repeatability of Ultrafiltration {#sec3dot5-molecules-23-01792}
-------------------------------------

Due to the potential for nonspecific binders to the HSA to lead to erroneous calculation, the repeatability of the bioactive ingredients in the SMD during ultrafiltration was studied. The repeatability showed the degree of affinity of these specific ingredients in SMD exhibiting large variety from 9.8--26.1% as shown in [Table 2](#molecules-23-01792-t002){ref-type="table"}, which might be caused by their structure types and proportions. Besides, the bioactivities of the targets might be affected by not only the binding properties but also the drug-like properties \[[@B56-molecules-23-01792]\], and the complicated components exhibited competitive relationships. Therefore, the binding degree in complex compounds might be different from that of single compounds. The relative standard deviation (RSD) of binding degrees of these binders was below 12.7%, indicating that each of the bioactive ligands could interact well with HSA.

3.6. Analysis of Molecular Docking {#sec3dot6-molecules-23-01792}
----------------------------------

In order to expound how bioactive drugs conjugate with HSA, a molecular docking simulation was used for further illustration in the active sites and binding degree of the ligands on HSA. The interactions of drugs with HSA typically occur at two major hydrophobic sites, known as Sudlow's site I (subdomain IIA) and site II (subdomain IIIA), which are located in subdomains \[[@B57-molecules-23-01792]\]. Many studies have verified that warfarin and ibuprofen were specific binders for site I and site II, respectively. In this study, the mode of specific docking (grid in site I and site II) showed more specific affinity than the full grid mode, indicating that these components were appropriate ligands of HSA. The simulation scores of the drugs to the two binding sites are listed in [Table 2](#molecules-23-01792-t002){ref-type="table"}.

To further investigate the interactions between ligands and binding sites, the ligands, narirutin and norisoboldine, with the highest scores of binding site I and site II, respectively, were analyzed. As shown in [Figure 5](#molecules-23-01792-f005){ref-type="fig"}A, narirutin easily inserted into site I with a docking score of −40.6 kJ/mol and was mainly surrounded by 30 amino acid residues within a range of 4 Å. These residues are believed to be important in the binding affinity. Three hydrogen bonds (dash lines) were formed on the 7-rutinose with Glu153, Lys199, and Arg257, respectively. Hydrophobic bonds were generated on the mother nucleus of the flavanone surrounded with 14 amino acid residues, as follows: Phe211, Trp214, Ala215, Arg218, Leu219, Arg222, Phe223, Leu238, Val241, Arg257, Leu260, Ile264, Ile290, and Ala291. As shown in [Figure 5](#molecules-23-01792-f005){ref-type="fig"}B, norisoboldine efficiently bound with site II and was mainly surrounded by 25 amino acid residues within a range of 4 Å. Two hydrogen bonds were formed on the 6-*N* and 9-C (OH) with Tyr411 and Arg458, respectively. Pro384, Leu387, Ile388, Phe403, Leu407, Val426, Leu430, Val 433, Ala449, Leu453, Leu457, Leu460, Phe488, and Leu491 surrounded the molecule forming hydrophobic bonds with a docking score at −36.1 kJ//mol.

It was found that the interactions between HSA and the flavonoids were dependent on the structures of the flavonoids. The glycoside of flavonoid was very important for the affinity degree, which mainly formed hydrogen bonds, while the A, B, and C rings supported hydrophobic bonds. In addition, in site I, as the number of methoxyl groups decreased, the affinity degree might increase. In site II, the docking scores of polymethoxy flavonoids were higher than at site I. This phenomenon was consistent with the tendency of site I to bind bulky heterocyclic anionic compounds and site II to aromatic carboxylates \[[@B57-molecules-23-01792]\]. Moreover, the effect of a hydroxyl on glycosyl was found to be less than that of a hydroxyl on the parent nucleus, perhaps because of the large area of steric hindrance \[[@B58-molecules-23-01792]\]. Although the current simulation studies could be considered efficient and reasonable, we also expect to further apply more advanced methods, such as fluorescence or X-ray, to explain the mechanisms of interactions between the bioactive ingredients and the related receptors, as well as the establishment of animal models to illustrate the metabolic pathways of effective constituents to clarify the pharmacological effects of SMD in future research.

4. Conclusions {#sec4-molecules-23-01792}
==============

In the current study, we established a simplified and effective strategy based on LC-Q-TOF-MS and UF-HPLC-MD for the identification of complicated ingredients and the screening of bioactive HSA ligands from SMD. A total of 94 compounds were identified or tentatively speculated by LC-Q-TOF-MS. Among them, nine compounds were derived from *Semen arecae*, 28 compounds were derived from *Radix linderae*, nine compounds were derived from *Radix aucklandiae*, and 40 compounds were derived from *Aurantii fructus*, in addition to the speculation of a further eight common compounds (e.g., amino acids). Flavonoids were abundant in these identified compounds in SMD ([Table 1](#molecules-23-01792-t001){ref-type="table"}). In addition, HSA binders from SMD were screened by the established UF-HPLC-MD method. A total of 13 bioactive ingredients was primarily illustrated as the specific HSA ligands in SMD which may be the main medicinal components. Molecular docking was employed for further illustration in the active site and binding degree of bioactive ligands on HSA.

SMD is widely used in the clinical treatment of gastrointestinal dynamic disorder, and these results provide reliable data to support the pharmacological research of SMD in the future. They also provide a reference for the reasonable combination of SMD with other methods or drugs in the treatment of gastrointestinal dysmotility. In addition, and compared with the conventional bioassay approach, the proposed strategy enables the rapid illustration of the identification and screening of bioactive components from complex mixtures.
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![Strategy based on liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-TOF-MS) and ultrafiltration high-performance liquid chromatography molecular docking (UF-HPLC-MD) method to identify and screen the bioactive ingredients in Simo decoction (SMD). HSA = human serum albumin; HPLC = high-performance liquid chromatography.](molecules-23-01792-g001){#molecules-23-01792-f001}

![Total ion chromatography of Simo decoction (SMD) in positive (**A**) and negative (**B**) modes.](molecules-23-01792-g002){#molecules-23-01792-f002}

###### 

The compounds were identified or preliminarily assigned from Simo decoction (SMD) based on the time-of flight-mass spectrometer.
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![The high-performance liquid chromatography (HPLC) chromatograms for screening of the human serum albumin (HSA) ligands in Simo decoction (SMD) after ultrafiltration and dissociation procedures. The blue solid line represents HPLC profile of SMD sample mixed with natured HSA, and the red and green lines represent HPLC profiles of SMD sample mixed with denatured HSA and buffer solution, respectively. Bioactive ligands (A--M) were identified as norisoboldine (A), eriocitrin (B), neoeriocitrin (C), narirutin (D), hesperidin (E), narigin (F), neohesperidin (G), hesperidin-7-*O*-glucoside (H), linderane (I), neoponcirin (J), costunolide (K), nobiletin (L), and tangeretin (M), respectively. Triangle (▼) represents a compound with a high response but no specific binding named "frequent hitters".](molecules-23-01792-g004){#molecules-23-01792-f004}

![Molecular docking of narirutin docked to site I (**A**) and norisoboldine docked to site II (**B**) of human serum albumin (HSA), respectively (Ligands were shown in stick form and gray dashed lines were hydrogen bonds. The figure was prepared with PyMol. The interactions between bioactive ligands and binding sites were detailed in the article).](molecules-23-01792-g005){#molecules-23-01792-f005}

molecules-23-01792-t001_Table 1

###### 

Identification of constituents from Simo decoction (SMD) by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-TOF-MS) analysis in positive and negative ion modes.

  No.                       T~R~ (min)   ESI+ (*m*/*z*)   ESI− (*m*/*z*)   Fragment Ions (Positive/Negative)        MW (Mea.)   MW (MFG)   Formula              Compound                                                Ref.                                                                                Error (ppm) ^b^
  ------------------------- ------------ ---------------- ---------------- ---------------------------------------- ----------- ---------- -------------------- ------------------------------------------------------- ----------------------------------------------------------------------------------- -----------------
  ***Areca catechu***                                                                                                                                                                                                                                                                                       
  **01**                    1.899        128.0704                          109.0289                                 127.0631    127.0633   C~6~H~9~NO~2~        Guvacine                                                \[[@B27-molecules-23-01792]\]                                                       1.61
  **02**                    2.113        142.0860                          /                                        141.0787    141.0790   C~7~H~11~NO~2~       Guvacoline                                              \[[@B27-molecules-23-01792]\]                                                       1.96
  **03**                    3.001        144.1021                          /                                        143.0948    143.0946   C~7~H~13~NO~2~       *N*-Methylnipecotic Acid                                \[[@B28-molecules-23-01792]\]                                                       −1.06
  **04**                    5.163        142.0864                          124.0252, 109.0289                       141.0791    141.0790   C~7~H~11~NO~2~       Arecaidine ^a^                                          \[[@B27-molecules-23-01792],[@B28-molecules-23-01792]\]                             −0.80
  **05**                    7.021        156.1018                          127.0410                                 155.0946    155.0946   C~8~H~13~NO~2~       Arecoline ^a^                                           \[[@B27-molecules-23-01792],[@B28-molecules-23-01792]\]                             0.24
  **06**                    16.247                        137.0240                                                  138.0312    138.0317   C~7~H~6~O~3~         4-Hydroxybenzoic acid                                   \[[@B43-molecules-23-01792]\]                                                       3.23
  **07**                    17.508       199.0597                                                                   198.0525    198.0528   C~9~H~10~O~5~        Syringic acid                                           \[[@B44-molecules-23-01792]\]                                                       1.62
  **08**                    19.379       291.0866                                                                   290.0793    290.0790   C~15~H~14~O~6~       Epicatechin                                             \[[@B44-molecules-23-01792]\]                                                       −0.93
  **09**                    25.337                        193.0500                                                  194.0572    194.0579   C~10~H~10~O~4~       Ferulic acid                                            \[[@B43-molecules-23-01792]\]                                                       3.4
  ***Radix linderae***                                                                                                                                                                                                                                                                                      
  **10**                    5.722        165.0545                                                                   164.0472    164.0473   C~9~H~8~O~3~         *p*-Coumaric acid                                       \[[@B29-molecules-23-01792]\]                                                       0.6
  **11**                    20.782       328.1546                                                                   327.1474    327.1471   C~19~H~21~NO~4~      Boldine                                                 \[[@B29-molecules-23-01792],[@B31-molecules-23-01792]\]                             −0.91
  **12**                    21.558       314.1388                          297.1125, 265.0839, 237.0743             313.1315    313.1314   C~18~H~19~NO~4~      Norboldine                                              \[[@B29-molecules-23-01792],[@B31-molecules-23-01792]\]                             −0.26
  **13**                    22.677       314.1387                          297.1141, 265.0787, 237.0619             313.1314    313.1314   C~18~H~19~NO~4~      Norisoboldine ^a^                                       \[[@B29-molecules-23-01792]\]                                                       −0.12
  **14**                    23.466       328.1543                          297.1110, 265.0859, 237.0627             327.1470    327.1471   C~19~H~21~NO~4~      Isoboldine                                              /                                                                                   0.03
  **15**                    24.093       261.1116                          243.1018, 173.0132                       260.1043    260.1049   C~15~H~16~O~4~       Linderane ^a^                                           \[[@B30-molecules-23-01792],[@B31-molecules-23-01792],[@B32-molecules-23-01792]\]   2.07
  **16**                    24.698       330.1698                          330.1691, 299.1472, 192.0682             329.1625    329.1627   C~19~H~23~NO~4~      Reticuline                                              \[[@B29-molecules-23-01792],[@B31-molecules-23-01792]\]                             0.57
  **17**                    25.234       263.1270                                                                   262.1197    262.1205   C~15~H~18~O~4~       Linderagalactone D                                      \[[@B30-molecules-23-01792],[@B31-molecules-23-01792]\]                             3.13
  **18**                    35.746       277.1068                                                                   276.0995    276.0998   C~15~H~16~O~5~       Linderanlide A                                          \[[@B32-molecules-23-01792]\]                                                       1.01
  **19**                    40.231       245.1169                                                                   244.1096    244.1099   C~15~H~16~O~3~       Neolinderalactone                                       \[[@B30-molecules-23-01792],[@B31-molecules-23-01792]\]                             1.50
  **20**                    40.590       291.1223                                                                   290.1150    290.1154   C~16~H~18~O~5~       Linderanlide D                                          \[[@B32-molecules-23-01792]\]                                                       1.51
  **21**                    44.323       305.1376                                                                   304.1303    304.1311   C~17~H~20~O~5~       Linderanlide F                                          \[[@B32-molecules-23-01792]\]                                                       2.54
  **22**                    46.623       263.1279                                                                   262.1207    262.1205   C~15~H~18~O~4~       Linderagalactone C                                      \[[@B30-molecules-23-01792]\]                                                       −0.57
  **23**                    47.462       247.1326                                                                   246.1254    246.1256   C~15~H~18~O~3~       Hydroylindestenolide isomer                             \[[@B29-molecules-23-01792]\]                                                       0.92
  **24**                    49.032       261.1117                                                                   260.1044    260.1049   C~15~H~16~O~4~       Linderane isomer                                        /                                                                                   1.64
  **25**                    50.118       247.1325                                                                   246.1252    246.1256   C~15~H~18~O~3~       Hydroylindestenolide                                    \[[@B30-molecules-23-01792],[@B31-molecules-23-01792]\]                             1.53
  **26**                    50.126       247.1329                                                                   246.1256    246.1256   C~15~H~18~O~3~       Lindenenol E                                            \[[@B29-molecules-23-01792]\]                                                       0.08
  **27**                    54.009       231.1380                                                                   230.1307    230.1307   C~15~H~18~O~2~       Lindenenol                                              \[[@B31-molecules-23-01792]\]                                                       −0.01
  ***Radix aucklandiae***                                                                                                                                                                                                                                                                                   
  **28**                    11.014       127.0388         /                                                         126.0315    126.0317   C~6~H~6~O~3~         5-HydroxymethylFurfual                                  \[[@B45-molecules-23-01792]\]                                                       1.24
  **29**                    25.283       193.0490                                                                   192.0417    192.0423   C~10~H~8~O~4~        5,7-dihydroxy-2-methylchromone                          \[[@B45-molecules-23-01792]\]                                                       2.89
  **30**                    44.022       233.1534                                                                   232.1461    232.1463   C~15~H~20~O~2~       Mokko lactone                                           \[[@B46-molecules-23-01792]\]                                                       0.91
  **31**                    46.101       233.1532                                                                   232.1459    232.1463   C~15~H~20~O~2~       Costunolide isomer                                      /                                                                                   1.84
  **32**                    47.095       233.1536                                                                   232.1464    232.1463   C~15~H~20~O~2~       Cyclocostunolide                                        \[[@B46-molecules-23-01792]\]                                                       −0.16
  **33**                    49.408       233.1530                          187.1475, 121.0516                       232.1457    232.1463   C~15~H~20~O~2~       Costunolide ^a^                                         \[[@B33-molecules-23-01792],[@B34-molecules-23-01792]\]                             2.75
  **34**                    49.895       235.1691                                                                   234.1618    234.1620   C~15~H~22~O~2~       Costus acid                                             \[[@B46-molecules-23-01792]\]                                                       0.71
  **35**                    51.221       239.2003                                                                   238.1930    238.1933   C~15~H~26~O~2~       4-*α*-hydroxy-4-*β*-methyldihydrocostol                 \[[@B46-molecules-23-01792]\]                                                       1.2
  **36**                    54.001       231.1373                                                                   230.1301    230.1307   C~15~H~18~O~2~       Dehydrocostus lactone ^a^                               \[[@B33-molecules-23-01792],[@B34-molecules-23-01792]\]                             2.69
  ***Aurantii fructus***                                                                                                                                                                                                                                                                                    
  **37**                    3.201                         191.0189                                                  192.0262    192.0270   C~6~H~8~O~7~         Citric acid                                             \[[@B37-molecules-23-01792],[@B47-molecules-23-01792]\]                             4.06
  **38**                    3.802        168.1017                                                                   167.0944    167.0946   C~9~H~13~NO~2~       Synephrine ^a^                                          \[[@B35-molecules-23-01792]\]                                                       1.45
  **39**                    9.369        268.1035                                                                   267.0962    267.0968   C~10~H~13~N~5~O~4~   Adenosine                                               \[[@B37-molecules-23-01792]\]                                                       2.03
  **40**                    17.108       196.0967                                                                   195.0894    195.0895   C~10~H~13~NO~3~      *N*-Acetylnorsynephrine                                 /                                                                                   0.8
  **41**                    20.439       611.1590                          465.0874, 303.0511                       610.1518    610.1534   C~27~H~30~O~16~      Quercetin-3-*O*-rutinoside (Rutin) ^a^                  \[[@B36-molecules-23-01792]\]                                                       2.53
  **42**                    21.337       595.1659         593.1500                                                  594.1587    594.1585   C~27~H~30~O~15~      Isovitexin-7-*O*-glucoside (Saponarin)                  \[[@B48-molecules-23-01792]\]                                                       −0.31
  **43**                    21.903       625.1766         623.1615         301.0723                                 624.1693    624.1690   C~28~H~32~O~16~      Diosmetin-6,8-*di*-*C*-glucoside                        \[[@B47-molecules-23-01792]\]                                                       −0.46
  **44**                    22.234                        741.2245         579.1833, 417.1323, 271.0756             742.2318    742.2320   C~33~H~42~O~19~      Naringenin-7-*O*-triglycoside                           \[[@B36-molecules-23-01792],[@B40-molecules-23-01792]\]                             0.36
  **45**                    22.377       625.1761                                                                   624.1688    624.1690   C~28~H~32~O~16~      Diosmetin 6,8-*di*-*C*-glucoside (isomer)               \[[@B47-molecules-23-01792]\]                                                       0.41
  **46**                    23.947       471.2007                                                                   470.1935    470.1941   C~26~H~30~O~8~       Limonin ^a^                                             \[[@B37-molecules-23-01792],[@B38-molecules-23-01792],[@B39-molecules-23-01792]\]   1.28
  **47**                    24.235       597.1813         595.1663         435.1278, 417.1185, 331.1826, 289.0702   596.1740    596.1741   C~27~H~32~O~15~      Eriodictyol-7-*O*-rutinoside (Eriocitrin) ^a^           \[[@B36-molecules-23-01792]\]                                                       0.12
  **48**                    24.460       481.1683                                                                   480.1610    480.1632   C~23~H~28~O~11~      Paeoniflorin, Albiflorin                                \[[@B40-molecules-23-01792]\]                                                       4.44
  **49**                    24.603                        649.2501                                                  650.2573    650.2575   C~32~H~42~O~14~      Limonin-17-*β*-[d]{.smallcaps}-glucoside                \[[@B39-molecules-23-01792],[@B49-molecules-23-01792]\]                             0.16
  **50**                    25.124       597.1807         595.1656         451.1287, 289.0699                       596.1735    596.1741   C~27~H~32~O~15~      Eriodictyol-7-*O*-neohesperidoside (Neoeriocitrin)      \[[@B36-molecules-23-01792],[@B37-molecules-23-01792]\]                             1.06
  **51**                    26.946                        461.1067                                                  462.1140    462.1162   C~22~H~22~O~11~      Diosmetin-7-*O*-glucoside                               \[[@B35-molecules-23-01792]\]                                                       4.85
  **52**                    26.986       595.1653                          463.1303, 287.0559                       594.1579    594.1585   C~27~H~30~O~15~      Luteolin-7-*O*-rutinoside (Veronicastroside)            /                                                                                   0.9
  **53**                    27.421       581.1853         579.1705         435.1274, 273.0757                       580.1781    580.1792   C~27~H~32~O~14~      Naringenin-7-*O*-rutinoside (Narirutin) ^a^             \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\]                             1.97
  **54**                    27.989       625.2107                          643.1461, 267.1224                       624.2034    624.2054   C~29~H~36~O~15~      Magnoloside A                                           \[[@B37-molecules-23-01792],[@B47-molecules-23-01792]\]                             3.31
  **55**                    28.694       581.1857         579.1687         435.1278, 419.1330, 273.0754, 153.0186   580.1785    580.1792   C~27~H~32~O~14~      naringenin-7-*O*-neohesperidoside (Naringin) ^a^        \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\]                             1.26
  **56**                    29.032       435.1274                          273.0757                                 434.1201    434.1213   C~21~H~20~O~10~      Naringenin-7-*O*-glucoside                                                                                                                  2.71
  **57**                    29.692       611.1965         609.1803         465.1432, 303.0858, 273.0757             610.1891    610.1898   C~28~H~34~O~15~      Hesperetin-7-*O*-rutinoside (Hesperidin) ^a^            \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\]                             1.13
  **58**                    30.385       579.1708         577.1549         433.1323, 271.0596                       578.1636    578.1636   C~27~H~30~O~14~      Apigenin-7-*O*-rutinoside (Isorhoifolin)                \[[@B40-molecules-23-01792]\]                                                       −0.01
  **59**                    31.051       611.1962         609.1811         465.1434, 303.0862, 153.0188             610.1889    610.1898   C~28~H~34~O~15~      Hesperetin-7-*O*-neohesperidoside (Neohesperidin) ^a^   \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\]                             1.37
  **60**                    31.121       465.1395                          331.1881, 303.0861, 155.0372, 121.0216   464.1322    464.1319   C~22~H~24~O~11~      Hesperitin-7-*O*-glucoside                              \[[@B37-molecules-23-01792]\]                                                       −0.73
  **61**                    31.638       609.1819                          463.1409, 301.0723                       608.1747    608.1741   C~28~H~32~O~15~      Diosmetin-7-*O*-rutinoside (Diosmin)                                                                                                        −0.88
  **62**                    32.515       609.1806                          463.1411, 301.0723                       608.1734    608.1741   C~28~H~32~O~15~      Diosmetin-7-*O*-neohesperidoside (Neodiosmin)           \[[@B47-molecules-23-01792]\]                                                       1.12
  **63**                    32.531                        693.2756                                                  694.2829    694.2837   C~34~H~46~O~15~      Nominin-17-*β*-[d]{.smallcaps}-glucoside                \[[@B39-molecules-23-01792],[@B49-molecules-23-01792]\]                             1.12
  **64**                    32.787                        651.1541                                                  652.1614    652.1639   C~29~H~32~O~17~      Obacunoic acid-17-*β*-[d]{.smallcaps}-glucoside         \[[@B39-molecules-23-01792]\]                                                       3.92
  **65**                    33.509                        711.2850                                                  712.2923    712.2942   C~34~H~48~O~16~      Nomilinic acid 17-*O*-*β*-[d]{.smallcaps}-glucoside     \[[@B39-molecules-23-01792],[@B49-molecules-23-01792]\]                             2.74
  **66**                    34.361       261.1120                                                                   260.1047    260.1049   C~15~H~16~O~4~       Meranzin hydrate                                        \[[@B50-molecules-23-01792]\]                                                       0.67
  **67**                    39.559       595.2016         593.1875         449.1505, 287.0917                       594.1944    594.1949   C~28~H~34~O~14~      Isosakuranetin-7-*O*-neohesperidoside, (Poncirin) ^a^   \[[@B36-molecules-23-01792],[@B41-molecules-23-01792]\]                             0.77
  **68**                    39.546       287.0913                                                                   286.0840    286.0841   C~16~H~14~O~5~       Oxypeucedanin                                           \[[@B48-molecules-23-01792]\]                                                       0.48
  **69**                    41.776       697.1975                                                                   696.1901    696.1902   C~31~H~36~O~18~      Isovitexin-7-*O*-xylocoside 2″-*O*-arabinoside          \[[@B40-molecules-23-01792]\]                                                       0.05
  **70**                    42.803       728.3970                                                                   727.3896    727.3905   C~36~H~53~N~7~O~9~   Citrusin III                                            \[[@B35-molecules-23-01792],[@B51-molecules-23-01792],[@B52-molecules-23-01792]\]   1.15
  **71**                    43.149                        271.0609                                                  272.0682    272.0685   C~15~H~12~O~5~       Naringenin ^a^                                          \[[@B36-molecules-23-01792]\]                                                       1.18
  **72**                    44.264       725.2283                                                                   724.2210    724.2215   C~33~H~40~O~18~      Melitidin                                               \[[@B53-molecules-23-01792]\]                                                       0.65
  **73**                    45.375                        301.0714                                                  302.0787    302.0790   C~16~H~14~O~6~       Hesperetin ^a^                                          \[[@B36-molecules-23-01792]\]                                                       1.27
  **74**                    47.003       704.3968                                                                   703.3895    703.3905   C~34~H~53~N~7~O~9~   Citrusin I                                              \[[@B52-molecules-23-01792]\]                                                       1.40
  **75**                    47.187       329.1023                          314.0762, 299.0543                       328.0950    328.0947   C~18~H~16~O~6~       Monohydroxytrimethoxyflavone                            \[[@B54-molecules-23-01792]\]                                                       −1.08
  **76**                    47.976       355.1533                                                                   354.1460    354.1467   C~21~H~22~O~5~       Epoxybergamottin or Cnidicin                            \[[@B55-molecules-23-01792]\]                                                       2.01
  **77**                    48.440       359.1119                          344.0877, 326.0771                       358.1046    358.1053   C~19~H~18~O~7~       5-Hydroxy-6,7,3′,4′-tetramethoxy-flavone                \[[@B54-molecules-23-01792]\]                                                       1.74
  **78**                    49.028       261.1117                                                                   260.1044    260.1049   C~15~H~16~O~4~       Meranzin, IsoMeranzin                                   \[[@B50-molecules-23-01792]\]                                                       1.64
  **79**                    49.634       471.2005                                                                   470.1932    470.1941   C~26~H~30~O~8~       Limonin isomer                                          \[[@B37-molecules-23-01792],[@B38-molecules-23-01792]\]                             1.76
  **80**                    50.227       373.1276                          358.1024, 343.0811                       372.1204    372.1209   C~20~H~20~O~7~       5,7,8,3′,4′-Pentamethoxyflavone (Isosinensetin)         \[[@B36-molecules-23-01792],[@B54-molecules-23-01792]\]                             1.44
  **81**                    50.853       373.1278                          358.1036, 343.0812                       372.1205    372.1209   C~20~H~20~O~7~       5,6,7,3′,4′-Pentamethoxyflavone (Sinensetin)            \[[@B54-molecules-23-01792]\]                                                       1.04
  **82**                    51.721       403.1385                          388.1025, 373.1253                       402.1312    402.1315   C~21~H~22~O~8~       5,6,7,8,3′,4′-Hexamethoxyflavone (Nobiletin) ^a^        \[[@B36-molecules-23-01792],[@B42-molecules-23-01792]\]                             0.74
  **83**                    51.847       433.1485                          403.1021, 388.0773                       432.1413    432.1420   C~22~H~24~O~9~       3′,4′,3,5,6,7,8-Heptamethox-yflavone                    \[[@B36-molecules-23-01792]\]                                                       1.79
  **84**                    52.030       343.1174                          328.0927, 285.0749                       342.1101    342.1103   C~19~H~18~O~6~       5,6,8,4′-Tetramethoxyflavone                            \[[@B54-molecules-23-01792]\]                                                       0.63
  **85**                    52.381       343.1175                          328.0919, 313.0705                       342.1102    342.1103   C~19~H~18~O~6~       4′,5,7,8-Tetramethoxyflavone                            \[[@B54-molecules-23-01792]\]                                                       0.36
  **86**                    53.099       373.1281                          358.1007, 343.1182                       372.1208    372.1209   C~20~H~20~O~7~       5,6,7,8,4′-Pentamethoxyflavone, (Tangeretin) ^a^        \[[@B36-molecules-23-01792],[@B42-molecules-23-01792]\]                             0.25
  **Common Compounds**                                                                                                                                                                                                                                                                                      
  **87**                    1.711        116.0705                                                                   115.0632    115.0633   C~5~H~9~NO~2~        Proline                                                 \[[@B38-molecules-23-01792]\]                                                       0.83
  **88**                    2.849        118.0865                                                                   117.0792    117.0790   C~5~H~11~NO~2~       Valine                                                  \[[@B38-molecules-23-01792]\]                                                       −1.83
  **89**                    4.328        132.1016                                                                   131.0943    131.0946   C~6~H~13~NO~2~       Isoleucine                                              \[[@B38-molecules-23-01792]\]                                                       2.32
  **90**                    4.678        132.1019                                                                   131.0947    131.0946   C~6~H~13~NO~2~       Leucine                                                 \[[@B38-molecules-23-01792]\]                                                       −0.32
  **91**                    5.813        182.0810                                                                   181.0737    181.0739   C~9~H~11~NO~3~       tyrosine                                                \[[@B38-molecules-23-01792]\]                                                       0.83
  **92**                    9.561        166.0859                                                                   165.0786    165.0790   C~9~H~11~NO~2~       Phenylalanine                                           \[[@B38-molecules-23-01792]\]                                                       2.36
  **93**                    17.316       205.0969                                                                   204.0896    204.0899   C~11~H~12~N~2~O~2~   Tryptophan                                              \[[@B38-molecules-23-01792]\]                                                       1.34
  **94**                    25.552       113.0597                                                                   112.0524    112.0524   C~6~H~8~O~2~         Sorbic acid ^a^                                         /                                                                                   0.25

^a^ Compound identified with standards; ^b^ The error (ppm \< 5 ppm) was obtained via the accurate mass data and formula predictor software of TOF mass spectrometer.MW (Mea.) = Molecular weight (measured); MW (MFG) = Molecular weight (molecular formula generated).
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###### 

Binding affinity (%) and docking score (kj/mol) of the ligands in Simo decoction (SMD) with human serum albumin (HSA).

  No.         Ligand                       Binding Affinity   Docking Score   
  ----------- ---------------------------- ------------------ --------------- -------
  A           Norisoboldine                26.1               −34.7           −36.1
  B           Eriocitrin                   14.2               −39.7           −30.5
  C           Neoeriocitrin                15.3               −38.9           −31.8
  D           Narirutin                    15.5               −40.6           −31.4
  E           Hesperidin                   11.6               −39.3           −30.1
  F           Naringin                     13.9               −39.7           −33.9
  G           Neohesperidin                12.8               −39.3           −30.1
  H           Hesperitin-7-*O*-glucoside   9.8                −36.4           −35.5
  I           Linderane                    22.5               −34.3           −36.0
  J           Poncirin                     16.7               −38.9           −31.0
  K           Costunolide                  19.6               −33.5           −35.9
  L           Nobiletin                    14.7               −32.2           −33.5
  M           Tangeretin                   12.9               −31.4           −34.7
  Drugs ^a^   Warfarin                     −                  −33.5           −
  Ibuprofen   −                            −                  −32.2           

^a^ The drugs warfarin and ibuprofen were specific ligands for site I and site II, respectively.

[^1]: These authors contributed equally to this work.
